7.2 Pharmacotherapy of Intra-abdominal, Hepatic, and GI Infections

Complicated Intra-Abdominal Infections (cIAI): Anatomy, Microbiology, and Severity Stratification

Intra-abdominal infections are anatomically and pathologically categorized as either uncomplicated (infection confined within a single hollow organ without anatomical disruption, such as uncomplicated appendicitis or diverticulitis) or complicated (cIAI). In cIAI, the infectious process extends beyond the organ of origin into the sterile peritoneal cavity, causing localized abscess formation, localized peritonitis, or diffuse, life-threatening generalized peritonitis.

Peritonitis Classification

• Primary Peritonitis (Spontaneous Bacterial Peritonitis [SBP]): Infection of pre-existing ascitic fluid without any gastrointestinal mucosal breach or surgically identifiable intra-abdominal source. It is characteristically monomicrobial (predominantly Enterobacterales or streptococci).
• Secondary Peritonitis: Direct consequence of a macroscopic breach in the alimentary tract integrity resulting from perforation, trauma, ischemia, anastomotic dehiscence, or transmural necrosis (e.g., perforated duodenal ulcer, gangrenous appendicitis, diverticular perforation). It is characteristically polymicrobial.
• Tertiary Peritonitis: Persistent, recurrent, or refractory intra-abdominal sepsis developing ≥ 48 hours following seemingly successful primary operative intervention for secondary peritonitis. It is characterized by low-virulence, highly resistant nosocomial opportunists (Enterococcus faecium, Candida species, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia), carrying an in-hospital mortality rate of 30–60%.

Microbiological Gradient Along the Alimentary Tract

The endogenous microflora changes dramatically along the craniocaudal axis of the human gastrointestinal tract, directly dictating empiric antimicrobial selection:

1. Stomach and Duodenum: Bacterial burden is kept low ($10^1 - 10^3$ CFU/mL) by gastric hydrochloric acid. Flora consists primarily of oral viridans streptococci, lactobacilli, and Candida species.
2. Jejunum and Proximal Ileum: Transition zone ($10^4 - 10^6$ CFU/mL) with increasing colonization by facultative Gram-negative Enterobacterales (Escherichia coli, Klebsiella species) and enterococci.
3. Distal Ileum and Colon: Massive microbial density ($10^{11} - 10^{12}$ CFU/gram of feces). Obligate anaerobes—dominated by the Bacteroides fragilis group (B. fragilis, B. thetaiotaomicron, B. vulgatus), Prevotella, Fusobacterium, and Clostridium species—outnumber facultative aerobic Gram-negative bacilli (E. coli, Klebsiella, Proteus, Enterobacter) by a ratio of 1,000:1.

Proximal Gastrointestinal Tract (Stomach / Duodenum)
  - Flora: Streptococci, Lactobacilli, Candida albicans
  - Low bacterial counts (10^1 - 10^3 CFU/mL)
                         │
                         ▼
Mid-Gastrointestinal Tract (Jejunum / Ileum)
  - Flora: Enterobacterales (E. coli, Klebsiella), Enterococcus faecalis
  - Intermediate density (10^4 - 10^7 CFU/mL)
                         │
                         ▼
Distal Gastrointestinal Tract (Distal Ileum / Colon)
  - Massive density (10^11 - 10^12 CFU/g)
  - Obligate Anaerobes outnumber Aerobes 1,000:1
  - Dominant Organisms: Bacteroides fragilis group, E. coli, Enterococci

Empiric Regimens Stratified by Risk and Setting

In accordance with Surgical Infection Society (SIS) and IDSA guidelines, empiric regimens are selected based on whether the infection is community-acquired (mild-to-moderate vs. high-risk/severe) or hospital-acquired/postoperative:

---

The Primacy of Source Control and the STOP-IT Landmark Evidence

Principles of Surgical Source Control

Antimicrobial pharmacotherapy represents an adjunctive intervention in complicated intra-abdominal infection; source control is the single most critical determinant of clinical outcome. Adequate source control comprises three essential surgical actions:

1. Drainage: Evacuation of all purulent exudates, purulent fluid collections, and encapsulated abscesses (via percutaneous catheter drainage or open laparotomy).
2. Debridement: Excision of non-viable, necrotic, or devitalized tissue (e.g., necrosectomy for infected pancreatic necrosis, debridement of ischemic omentum).
3. Definitive Anatomical Repair: Interruption of ongoing visceral soilage and restoration of gastrointestinal tract integrity (e.g., appendectomy, cholecystectomy, resection of perforated bowel with exteriorization or primary anastomosis).

The Landmark STOP-IT Trial Evidence

Historically, post-source control antimicrobial regimens were continued arbitrarily for 10 to 14 days, or until every inflammatory parameter (body temperature, total leukocyte count, gastrointestinal motility) had completely normalized.

The STOP-IT Trial (Study to Optimize Peritoneal Infection Therapy; Sawyer et al., NEJM 2015) transformed clinical practice:

• Study Design: A multicenter randomized controlled trial evaluating 518 patients with complicated intra-abdominal infections who achieved adequate surgical or percutaneous source control.
• Intervention:
  • Experimental Group (Fixed Short-Course): Antibiotics administered for a fixed duration of 4 ± 1 days (median 4.0 days) post-source control procedure.
  • Control Group (Traditional Practice): Antibiotics continued until 2 full calendar days after complete resolution of fever, leukocytosis, and resumption of oral intake, up to a maximum of 10 days (median 8.0 days).
• Results:
  • The primary composite endpoint of surgical-site infection, recurrent intra-abdominal infection, or death occurred in 21.8% of patients in the short-course group versus 22.3% in the traditional group (absolute difference -0.5%, 95% CI -7.0 to 8.0, p=0.92).
  • There were no statistically significant differences in recurrent abscesses (15.6% vs 15.8%), surgical-site infections (6.8% vs 8.8%), or 30-day all-cause mortality (1.2% vs 1.2%).
• Clinical Guideline Consensus: In patients with complicated intra-abdominal infections who achieve definitive source control, a fixed 4-day (96-hour) antimicrobial course is fully non-inferior to traditional extended courses. Prolonging therapy provides zero clinical protection against recurrent collections; instead, it selects for multidrug-resistant pathogens and promotes Clostridioides difficile colitis.

---

Clostridioides difficile Infection (CDI): 2021 IDSA/SHEA Guidelines and 2026 Standards

Pathophysiology and Clinical Risk Factors

Clostridioides difficile is an obligate anaerobic, spore-forming Gram-positive bacillus transmitted via the fecal-oral route. Inoculated spores resist gastric acidity, germinate in the small bowel, and colonize the colonic lumen when native microflora (Bacteroidetes and Firmicutes) has been decimated by systemic antimicrobial exposure.

Vegetative cells elaborate two potent exotoxins:

• Toxin A (enterotoxin) and Toxin B (cytotoxin) bind apical colonocyte receptors, enter cells via receptor-mediated endocytosis, and irreversibly monoglucosylate host Rho and Rac GTPases.
• This disrupts the cellular actin cytoskeleton, disassembles tight junctions, triggers epithelial apoptosis, and incites a massive transmural neutrophil infiltration leading to yellow-white mucosal pseudomembranes.
• Hypervirulent ribotype BI/NAP1/027 carries a deletion in the negative regulatory gene tcdC, leading to hyperproduction of Toxins A and B alongside binary toxin (CDT).

Major antimicrobial precipitants of CDI include: clindamycin, fluoroquinolones, third- and fourth-generation cephalosporins, and carbapenems. Non-antimicrobial risk factors include: age ≥ 65 years, hospitalization, chemotherapy, chronic kidney disease, and gastric acid suppression (proton pump inhibitors).

Antibiotic Exposure Disrupts Native Colonic Microflora
                        │
                        ▼ Ingestion & Germination of C. difficile Spores
Vegetative C. difficile Colonization & Overgrowth
                        │
                        ▼ Elaboration of Toxin A & Toxin B
Monoglucosylation of Host Rho / Rac Family GTPases
                        │
       ┌────────────────┴────────────────┐
       ▼                                 ▼
Cytoskeleton Breakdown &          Release of Pro-inflammatory Chemokines
Epithelial Cell Apoptosis         (Massive Neutrophil Infiltration)
       │                                 │
       └────────────────┬────────────────┘
                        │
                        ▼
Pseudomembrane Formation & Secretory Diarrhea

Disease Severity Stratification (IDSA/SHEA Criteria)

Accurate classification into non-severe, severe, or fulminant CDI is essential to direct initial therapy:

1. Non-Severe CDI: White blood cell (WBC) count ≤ 15,000 cells/mcL AND Serum Creatinine (SCr) < 1.5 mg/dL.
2. Severe CDI: WBC count ≥ 15,000 cells/mcL OR Serum Creatinine ≥ 1.5 mg/dL (or a >50% increase over pre-morbid baseline).
3. Fulminant CDI: Severe CDI complicated by hypotension, septic shock, ileus, or toxic megacolon.

Pharmacotherapy of CDI (Initial Episode)

In the 2021 IDSA/SHEA focused update, fidaxomicin was established as the preferred first-line agent over oral vancomycin for both non-severe and severe initial CDI:

• Preferred First-Line Regimen: Fidaxomicin 200 mg PO twice daily for 10 days.
  • Mechanism: Narrow-spectrum macrocyclic inhibitor of bacterial RNA polymerase with high selectivity for clostridial species.
  • Advantage: Spares normal commensal fecal Bacteroidetes and Clostridial cluster organisms. While achieving initial clinical cure rates equivalent to vancomycin (~88%), fidaxomicin produces a 40–50% relative reduction in 30-day disease recurrence compared to vancomycin.
• Alternative First-Line Regimen: Vancomycin 125 mg PO four times daily for 10 days.
  • Mechanism: Poorly absorbed glycopeptide that achieves high intraluminal fecal concentrations (>1,000 mcg/g).
  • Crucial Rule: Intravenous vancomycin is completely ineffective for CDI. It does not undergo biliary excretion or active transtubular transport across the bowel wall, yielding zero active drug in the colonic lumen.
• Metronidazole Role Demotion: Oral metronidazole (500 mg PO three times daily for 10–14 days) is strictly restricted to non-severe initial episodes only when fidaxomicin and oral vancomycin are unavailable or unaffordable. It is clinically inferior to vancomycin and carries risks of cumulative peripheral and central neurotoxicity.

Management of Fulminant CDI

Fulminant CDI is a life-threatening medical emergency requiring aggressive multi-modal pharmacotherapy and urgent surgical consultation:

Fulminant CDI: Hypotension, Shock, Ileus, or Toxic Megacolon
                          │
                          ▼
  1. Vancomycin 500 mg PO or via NG tube QID
  2. PLUS Metronidazole 500 mg IV every 8 hours
  3. If Ileus Present: Add Vancomycin Retention Enemas
     (500 mg in 100 mL NS rectally via Foley catheter q6h)
  4. Urgent Surgical Consultation for Subtotal Colectomy or
     Diverting Loop Ileostomy with Antegrade Vancomycin Lavage

• Pharmacotherapy: Vancomycin 500 mg PO or via nasogastric tube four times daily PLUS Metronidazole 500 mg IV every 8 hours.
  • High-dose oral vancomycin overcomes disrupted peristalsis.
  • Intravenous metronidazole is critical because it is secreted into the inflamed, hyperemic colonic mucosa and biliary tree, delivering active drug to ischemic or obstructed bowel segments that oral vancomycin cannot reach.
• Management of Adynamic Ileus: If paralytic ileus or toxic megacolon is present, orally administered vancomycin cannot traverse past the aperistaltic small intestine. Therefore, vancomycin retention enemas (500 mg dissolved in 100 mL 0.9% sodium chloride instilled rectally via an 18-French Foley catheter with balloon inflation for 30–60 minutes every 6 hours) must be administered.
• Surgical Source Control: Emergency subtotal colectomy with end-ileostomy or diverting loop ileostomy with intraoperative antegrade colonic vancomycin lavage (Neal procedure) is indicated prior to bowel perforation or serum lactate exceeding 5.0 mmol/L.

Recurrent CDI Management

Recurrence occurs in 15–30% of patients following a first episode and escalates to 40–65% following a second recurrence:

1. First Recurrence:
   • If vancomycin was used initially: Fidaxomicin 200 mg PO BID for 10 days OR pulsed-tapered fidaxomicin (200 mg PO BID days 1–5, then once every other day days 6–25).
   • If fidaxomicin was used initially: Pulsed-tapered fidaxomicin OR a prolonged vancomycin taper/pulse regimen (125 mg PO QID x 10–14 days, then BID x 7 days, then daily x 7 days, then every 2–3 days for 2–8 weeks).
   • Bezlotoxumab: A fully humanized IgG1 monoclonal antibody directed against C. difficile Toxin B. Administered as a single intravenous infusion (10 mg/kg) during active oral antibiotic therapy. In the MODIFY I/II trials, bezlotoxumab reduced recurrent CDI by approximately 40% in high-risk patients (age ≥ 65, immunocompromised, severe CDI, or prior recurrence within 6 months). Caution: Carries an alert for increased heart failure exacerbations in patients with pre-existing congestive heart failure. Availability: Merck, the sole supplier, discontinued bezlotoxumab in January 2025, so it is no longer a practical option in the United States; recurrence prevention now rests on fidaxomicin, vancomycin taper/pulse, and microbiome restoration therapy. Expect the exam to test the toxin B target and the heart failure warning rather than current ordering.
2. Second or Subsequent Recurrences:
   • Treat the acute episode with vancomycin taper/pulse or fidaxomicin, followed by microbiome restoration therapy:
   • Fecal Microbiota Transplantation (FMT): Infusion of healthy donor fecal suspension via colonoscopy or retention enema, achieving >85–90% sustained resolution.
   • FDA-Approved Live Biotherapeutic Products:
     • RBX2660 (Rebyota): Rectally administered broad-consortium fecal microbiota suspension.
     • SER-109 (Vowst): Orally administered encapsulated consortium of purified bacterial spores from the Firmicutes phylum, taken as 4 capsules daily for 3 consecutive days following antibiotic completion and a magnesium citrate bowel cleanse.

---

Spontaneous Bacterial Peritonitis (SBP) and Cirrhotic Ascites

Pathogenesis and Diagnostic Criteria

Spontaneous bacterial peritonitis develops in patients with advanced cirrhosis and portal hypertension. Intestinal mucosal edema, bacterial overgrowth, and impaired local immunity permit bacterial translocation from the gut lumen into mesenteric lymph nodes, with subsequent hematogenous seeding of ascitic fluid. Cirrhotic ascites has deficient complement levels and low opsonic activity, fostering bacterial proliferation.

Microbiology is predominantly monomicrobial:

• Escherichia coli (~40%)
• Klebsiella pneumoniae (~20%)
• Streptococcus pneumoniae and other Streptococci (~15–20%)
• Enterococci (~5–10%)
• Anaerobes are exceedingly rare (<1%) due to the high oxygen tension of ascitic fluid.

Diagnostic Paracentesis

Diagnostic paracentesis is mandatory in any cirrhotic patient with ascites admitted to the hospital, or demonstrating signs of infection, abdominal pain, fever, altered mental status (hepatic encephalopathy), gastrointestinal bleeding, or unexplained renal failure.

Distinguishing SBP from Secondary Peritonitis (Runyon's Criteria): Suspect secondary peritonitis due to visceral perforation if the ascitic culture is polymicrobial or if the fluid satisfies at least 2 of the following 3 criteria: total protein >1.0 g/dL, glucose <50 mg/dL, and LDH > upper limit of normal for serum. Secondary peritonitis requires emergent surgical evaluation.

Pharmacotherapy and Adjunctive Intravenous Albumin

• Empiric Antimicrobial Therapy: Ceftriaxone 2 g IV every 24 hours (or Cefotaxime 2 g IV every 8 hours) for a duration of 5 days. Clinical response is evidenced by resolution of fever and abdominal pain; routine follow-up paracentesis is not necessary if the patient demonstrates unequivocal clinical improvement.
• Severe Beta-Lactam Allergy: Intravenous ciprofloxacin (400 mg q12h) or levofloxacin (750 mg q24h) may be used, provided the patient has not been receiving long-term fluoroquinolone prophylaxis.
• Adjunctive Intravenous Albumin Therapy:
  • Mechanism: SBP induces systemic vasodilation and worsening of effective arterial blood volume, precipitating type-1 hepatorenal syndrome (HRS) in up to 30% of patients. Intravenous albumin expands intravascular oncotic volume, binds bacterial endotoxins, and scavenges nitric oxide.
  • Landmark Evidence (Sort et al., NEJM 1999): Patients randomized to receive ceftriaxone plus IV albumin demonstrated a reduction in renal impairment from 33% to 10% and in-hospital mortality from 29% to 10% (p=0.01).
  • Dosing Protocol: Albumin 1.5 g/kg IV within 6 hours of diagnosis, followed by Albumin 1.0 g/kg IV on Day 3.
  • Target Population: While all patients benefit, the mortality reduction is most pronounced in high-risk patients with baseline serum bilirubin ≥ 4.0 mg/dL, blood urea nitrogen (BUN) ≥ 30 mg/dL, or serum creatinine ≥ 1.0 mg/dL.

Prophylactic Antimicrobial Strategies

Cirrhotic patients with ascites require targeted antimicrobial prophylaxis in three specific high-risk clinical scenarios:

1. Acute Upper Gastrointestinal Hemorrhage: Cirrhotic patients experiencing acute variceal bleeding carry a 40–50% risk of developing severe bacterial infections (SBP and bacteremia) due to mucosal disruption and bacterial translocation. Prophylaxis with Ceftriaxone 1 g IV every 24 hours for up to 7 days (transitioned to oral ciprofloxacin once bleeding is controlled and oral intake tolerated) significantly reduces bacterial infections, re-bleeding rates, and overall mortality.
2. Secondary Prophylaxis (Post-SBP Recovery): Following a single documented episode of SBP, the 1-year cumulative recurrence rate approaches 70%. Indefinite daily oral prophylaxis with Ciprofloxacin 500 mg daily or Trimethoprim-Sulfamethoxazole (TMP-SMX) 1 DS tablet (160/800 mg) daily is mandatory until liver transplantation or complete permanent resolution of ascites.
3. Primary Prophylaxis: Indicated for patients with low-protein ascitic fluid (<1.5 g/dL) who possess advanced hepatic dysfunction (Child-Pugh score ≥ 9 with bilirubin ≥ 3 mg/dL) or renal dysfunction (serum creatinine ≥ 1.2 mg/dL, BUN ≥ 25 mg/dL, or serum sodium ≤ 130 mEq/L): Daily oral Ciprofloxacin 500 mg or TMP-SMX 1 DS tablet.

---

Biliary Tract Infections: Acute Cholecystitis and Ascending Cholangitis

Acute Cholecystitis (Tokyo Guidelines TG18/TG26)

Acute cholecystitis is inflammation of the gallbladder initiated by cystic duct obstruction by gallstones (calculous cholecystitis in >90% of cases). Mechanical duct occlusion elevates intraluminal pressure, compromising mucosal venous and arterial perfusion, leading to chemical inflammation followed by secondary bacterial superinfection.

• Microbiology: Enteric Gram-negative bacilli (E. coli, Klebsiella pneumoniae, Enterobacter), Enterococcus species, and occasionally anaerobes (predominantly in elderly patients or following biliary-enteric anastomosis).
• Diagnostic Criteria: Local signs of gallbladder inflammation (Murphy's sign, right upper quadrant pain/mass/tenderness) + Systemic signs of inflammation (fever, elevated CRP, leukocytosis) + Ultrasound or CT imaging confirming gallbladder wall thickening (≥ 4 mm), pericholecystic fluid, or gallbladder distension.
• Management:
  • Mild (Grade I): Intravenous Cefazolin (2 g q8h) or Ceftriaxone (1–2 g q24h).
  • Moderate to Severe (Grade II/III): Intravenous Piperacillin-tazobactam (3.375 g q6h) or Cefepime (2 g q8h) + Metronidazole (500 mg q8h).
  • Source Control: Early laparoscopic cholecystectomy (within 72 hours of symptom onset) is the treatment of choice. Postoperatively, antimicrobials should be discontinued within 24 hours of successful cholecystectomy unless gallbladder gangrene, perforation, or peritonitis is documented.

Acute Ascending Cholangitis: Charcot's Triad and Reynolds' Pentad

Acute ascending cholangitis is an emergency characterized by biliary outflow obstruction (choledocholithiasis, benign strictures, or malignant compression) combined with bacterial infection of the intrahepatic biliary tree.

• Pathophysiology: As bile stasis persists, intrabiliary pressure escalates above 25–30 cm H2O. When intraductal pressure exceeds normal hepatic venous secretion pressure, the blood-biliary barrier breaks down, precipitating massive retrograde reflux of bacteria and endotoxins into the hepatic circulation and vena cava, rapidly inducing septic shock.
• Clinical Presentation:
  • Charcot's Triad: Fever/Chills, Jaundice, and Right Upper Quadrant Abdominal Pain (present in 50–70% of cases).
  • Reynolds' Pentad: Charcot's triad PLUS Hypotension (Septic Shock) PLUS Altered Mental Status (Confusion). Reynolds' pentad indicates acute suppurative ascending cholangitis, a catastrophic condition carrying near 100% mortality without emergent intervention.

Biliary Outflow Obstruction (Choledocholithiasis, Malignancy)
                         │
                         ▼ Biliary Stasis & Microbial Proliferation
Marked Elevation in Intrabiliary Pressure (> 25-30 cm H2O)
                         │
                         ▼ Disruption of Blood-Biliary Tight Junctions
Massive Retrograde Translocation of Bacteria into Hepatic Venous System
                         │
       ┌─────────────────┴─────────────────┐
       ▼                                   ▼
Charcot's Triad                     Reynolds' Pentad
(Fever, Jaundice, RUQ Pain)         (Charcot's Triad + Hypotension + Confusion)
       │                                   │
       └─────────────────┬─────────────────┘
                         │
                         ▼
  1. Aggressive IV Fluid Resuscitation
  2. Broad-Spectrum IV Antimicrobial Therapy (e.g., Piperacillin-Tazobactam)
  3. EMERGENT BILIARY DECOMPRESSION (ERCP with Stent / Sphincterotomy)

• Pharmacotherapy: Initiate immediate broad-spectrum bactericidal intravenous therapy: Piperacillin-tazobactam (3.375–4.5 g IV every 6 hours) OR Meropenem (1 g IV every 8 hours) OR Ceftriaxone (2 g IV every 24 hours) PLUS Metronidazole (500 mg IV every 8 hours).
• Duration of Therapy: Continue antimicrobials for 4 to 5 days following successful biliary decompression and clinical defervescence. If bacteremia is documented on initial blood cultures, continue targeted therapy for a minimum of 7 days.